The company that decided to build the door instead of the drug.
Somewhere in a lab in Watertown, Massachusetts, a cell is about to have the strangest few milliseconds of its life. It is flowing through a channel, minding its own biological business, when it meets a microscopic hole in a thin silicon surface. The hole is slightly too small. The cell squeezes. Its membrane - the wall that keeps the inside in and the outside out - stretches and, for an instant, opens. In rushes the cargo: a strand of mRNA, a snippet of siRNA, a CRISPR complex, a protein. Then the cell moves on, reseals, and gets back to work, now carrying instructions it did not have a second ago.
That instant is Portal Biotechnologies' entire business. Not the drug that the cargo might one day become. Not the therapy. The doorway.
It is a deliberately unglamorous place to plant a flag. Biotech mythology is built around molecules with names and patents and clinical trials - the blockbuster, the cure, the IPO bell. Portal, founded in December 2023, sells none of that. It sells instruments and single-use silicon consumables to the people making the molecules. In a gold rush, Portal is in the shovel business.
Here is the thing every gene therapy, RNA drug, and engineered-cell program eventually collides with: the cell membrane is very good at its job. Getting a large, complex payload across it - without killing the cell - is the quiet chokepoint the whole field depends on. Viruses can do it, but they come with baggage. Chemistry can do it, but not for everything. Electricity can do it, but roughly.
Portal's answer is mechanical. Squeeze the cell, open the membrane for a heartbeat, let the cargo diffuse in, and let physics reseal the wall. Because the trick is physical rather than chemical or viral, it is broadly indifferent to what you are delivering. mRNA, siRNA, polypeptides, CRISPR RNP complexes - the platform treats them all as cargo. That indifference is the point. When the industry is still arguing over which payload wins, Portal has quietly decided to be the road rather than the truck.
None of this is Armon Sharei's first rodeo. The idea traces back to his PhD research at MIT, where he worked out how to squeeze material into cells without destroying them. He turned that into SQZ Biotechnologies, took it from invention to a post-IPO public company, and then did the thing few founders can bring themselves to do: he left, and started smaller.
Portal is the sharper, more focused version of the same conviction. Where SQZ set out to make cell therapies, Portal set out to make the tools others use to make them - and to make those tools reliable enough to disappear into the background of a working lab. More than 100 customer sites now run the platform, including seven of the ten largest pharmaceutical companies on earth. Over fifty biopharma and academic partners signed on, many before the seed round even closed.
A family of delivery instruments and consumables - designed to slot into the workflows labs already run.
Portal's foundational mechanical delivery system - the instrument and silicon consumables that push cargo into cells as they transit microscopic holes.
Higher-throughput members of the line, built for multiplexed, massively parallel cargo delivery across many cell types at once.
A companion product supporting scaled and enhanced delivery workflows as programs move from bench to production.
The squeeze-based approach behind it all - applied to jobs like cytosolic antigen delivery and CD8 T cell activation.
"To get something into a cell, briefly break the cell - then let it heal."
- The counterintuitive idea at the heart of Portal's platform
Roughly $12M+ raised across pre-seed and seed, plus non-dilutive government backing.
Investors include Pear VC, IA Ventures, Conscience VC, 10x Capital, Undeterred Ventures, Page One Ventures, IKJ Capital and NFX. *Follow-on figure reported publicly; treat as approximate. A separate ~$8M DARPA contract funds a portable, point-of-care cell engineering device.
Portal emerges from stealth, launching its next-generation mechanical cell-delivery platform.
Raises a $5M pre-seed round led by Pear VC, with Conscience VC and 10x Capital.
Closes an oversubscribed $7M seed round led by IA Ventures - 50+ partners already onboard.
Reports 100+ customer sites, a DARPA contract, and follow-on capital to scale commercial adoption.
Return to that cell in the Watertown lab - the one squeezing through a hole slightly too small, membrane open for a heartbeat. A year ago, that moment was a party trick from an MIT thesis, a clever way to get molecules across a wall. Today it is repeated, quietly, across more than a hundred labs, in the workflows of seven of the ten biggest drug companies in the world, in a device DARPA wants to make small enough to carry to a patient.
The cell reseals and moves on, carrying instructions it did not have a second ago. It will not know it passed through anything called Portal. That is the whole idea. The best infrastructure disappears - you notice the plumbing only when it fails, and you build a durable company by owning a piece of everything built on top of it. Portal is betting that the future of medicine runs through a door most people will never see, opened for a heartbeat, then closed again.